TW200628158A - Promoting neochondrogenesis using kinase inhibitors - Google Patents

Promoting neochondrogenesis using kinase inhibitors

Info

Publication number
TW200628158A
TW200628158A TW094134143A TW94134143A TW200628158A TW 200628158 A TW200628158 A TW 200628158A TW 094134143 A TW094134143 A TW 094134143A TW 94134143 A TW94134143 A TW 94134143A TW 200628158 A TW200628158 A TW 200628158A
Authority
TW
Taiwan
Prior art keywords
neochondrogenesis
promoting
kinase inhibitors
compounds
methods
Prior art date
Application number
TW094134143A
Other languages
Chinese (zh)
Inventor
Vijaykumar Mahalingappa Baragi
David Wayne Brammer
Cynthia Lee Courtney
Brian Craig Korniski
Charles Alfred Lesch
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35447209&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200628158(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of TW200628158A publication Critical patent/TW200628158A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention provides methods for utilizing compounds that inhibit cyclin-dependent kinase and tyrosine kinase enzymes in the promotion of neochondrogenesis and the enhancement, protection and repair of cartilage. In certain embodiments the invention relates to methods of using compounds of formula I: , and pharmaceutically acceptable salts thereof, to promote neochondrogenesis, wherein, R1, R2, R3, R4, R5, R6, A, B, D, and E have any of the values defined therefor in the specification.
TW094134143A 2004-10-01 2005-09-30 Promoting neochondrogenesis using kinase inhibitors TW200628158A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US61548804P 2004-10-01 2004-10-01

Publications (1)

Publication Number Publication Date
TW200628158A true TW200628158A (en) 2006-08-16

Family

ID=35447209

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094134143A TW200628158A (en) 2004-10-01 2005-09-30 Promoting neochondrogenesis using kinase inhibitors

Country Status (2)

Country Link
TW (1) TW200628158A (en)
WO (1) WO2006038112A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007071752A2 (en) 2005-12-21 2007-06-28 Novartis Ag Pyrimidinyl aryl urea derivatives being fgf inhibitors
EP1882475A1 (en) * 2006-07-26 2008-01-30 Novartis AG Method of treating disorders mediated by the fibroblast growth factor receptor
MX2010002449A (en) 2007-08-31 2010-09-07 Purdue Pharma Lp Substituted-quinoxaline-type-piperidine compounds and the uses thereof.
WO2011065800A2 (en) * 2009-11-30 2011-06-03 주식회사 오스코텍 Pyrimidine derivative, method for preparing same and pharmaceutical composition containing same
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
PT3495367T (en) 2012-06-13 2020-11-12 Incyte Holdings Corp Substituted tricyclic compounds as fgfr inhibitors
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
TWI647220B (en) 2013-03-15 2019-01-11 美商西建卡爾有限責任公司 Heteroaryl compound and its use
NZ711376A (en) 2013-03-15 2020-01-31 Sanofi Sa Heteroaryl compounds and uses thereof
AU2014228746B2 (en) 2013-03-15 2018-08-30 Celgene Car Llc Heteroaryl compounds and uses thereof
TWI715901B (en) 2013-04-19 2021-01-11 美商英塞特控股公司 Bicyclic heterocycles as fgfr inhibitors
AU2014337291B9 (en) 2013-10-18 2020-05-07 Eisai R&D Management Co., Ltd. Pyrimidine FGFR4 inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CN104478742A (en) * 2014-11-24 2015-04-01 苏州乔纳森新材料科技有限公司 Fluoro compound and preparation method thereof
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
CN113004278B (en) 2015-02-20 2023-07-21 因赛特控股公司 Bicyclic heterocycles as FGFR inhibitors
MA41551A (en) 2015-02-20 2017-12-26 Incyte Corp BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
MX2017013248A (en) 2015-04-14 2018-07-06 Eisai R&D Man Co Ltd Crystalline fgfr4 inhibitor compound and uses thereof.
EP3454898B1 (en) 2016-05-10 2021-11-10 Eisai R&D Management Co., Ltd. Drug combinations for reducing cell viability and/or cell proliferation
AR111960A1 (en) 2017-05-26 2019-09-04 Incyte Corp CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
JOP20190282A1 (en) 2017-06-09 2019-12-05 Novartis Ag Compounds and compositions for inducing chondrogenesis
CR20200591A (en) 2018-05-04 2021-03-31 Incyte Corp Salts of an fgfr inhibitor
WO2019213544A2 (en) 2018-05-04 2019-11-07 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
TW202128685A (en) 2019-10-14 2021-08-01 美商英塞特公司 Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3162010A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20021744A3 (en) * 1999-10-21 2002-08-14 F. Hoffmann-La Roche Ag Bicyclic nitrogen heterocycles substituted with heteroalkylamino group functioning as P38 protein kinase inhibitors
BR0112857A (en) * 2000-08-04 2005-02-09 Warner Lambert Co 2- (4-Pyridyl) amino-6-dialkoxyphenyl-pyrido- [2,3-d] pyrimidin-7-ones compounds
US7196090B2 (en) * 2002-07-25 2007-03-27 Warner-Lambert Company Kinase inhibitors

Also Published As

Publication number Publication date
WO2006038112A1 (en) 2006-04-13

Similar Documents

Publication Publication Date Title
TW200628158A (en) Promoting neochondrogenesis using kinase inhibitors
TW200745028A (en) Novel sulphonylpyrroles
TW200745027A (en) Novel sulphonylpyrroles
DK1836201T3 (en) Pyrrolidine Inhibitors of IAP
UA85593C2 (en) Quinazolinone derivatives as parp inhibitors
TW200600499A (en) Novel amido-substituted hydroxy-6-phenylphenanthridines
MY142441A (en) Azole derivatives as inhibitors of lipases and phospholipases
PL372926A1 (en) Piperidine-pyridazones and phthalazones as pde4 inhibitors
MXPA06012595A (en) Amino-tetrazoles analogues and methods of use.
MX2007003546A (en) Indozolone derivatives as 11b-hsd1 inhibitors.
IL185275A0 (en) N-sulphonylpyrrole derivatives and pharmaceutical compositions containing the same
SG154432A1 (en) Quinazolinedione derivatives as parp inhibitors
TNSN08178A1 (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
WO2005087724A3 (en) Sulphonylpyrroles as hdac inhibitors
GEP20094679B (en) Dipeptidyl peptidase inhibitors
ATE533485T1 (en) CETP INHIBITORS
GEP20084421B (en) Proline derivatives and their use as dipeptidyl peptidase iv inhibitors
MX2009004441A (en) Indazole derivatives useful as l-cpt1 inhibitors.
HK1115590A1 (en) Triazolophthalazines
TW200730513A (en) Carbamoylbenzotriazole derivatives as inhibitors of lipases and phospholipases
ATE553093T1 (en) INDAZOLE DERIVATIVES FOR INHIBITING TRPV1 AND USES THEREOF
MXPA06013387A (en) Novel pyridazinone derivatives as inhibitors of cdk2.
ATE553106T1 (en) HETEROARYLPYRROLOPYRIDINONES AS KINASE INHIBITORS
TW200745074A (en) New pharmaceutical compounds
MX2010007391A (en) Trpa1 antagonists.